Portola pharmaceuticals history


. Nov 7, 2018 November 07, 2018 16:05 ET | Source: Portola Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. EST Technology Fast 500 2017 NORTH AMERICA 500 Where are Portola Pharmaceuticals' (NASDAQ:PTLA) earnings headed? View PTLA's earnings history and consensus earnings estimates from top-rated Wall Street analysts at MarketBeat. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. or Login. Portola Pharmaceuticals Inc. Consensus Rating for PTLA is STRONG BUY: Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. 10%)Get Portola Pharmaceuticals Inc (PTLA:NASDAQ) real-time stock quotes, news and financial information from CNBC. Looking at the Portola Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Tuesday, December 11, 2018. Betrixaban, a long-acting oral factor Xa inhibitor, is being developed by Portola Pharmaceuticals for the prevention of venous thromboembolism in acute Based in South San Francisco, California, Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. Biogen Idec’s inaugural Care Deeply Volunteer Day kicks off. As announced by Portola Pharmaceuticals, Inc. , a biopharmaceutical company ("Portola"), since co-founding the company in 2003 until 2010. Thursday, May 03, 2018. Subscribe to MarketWatch's free Bulletin emails. Comprehensive benchmarks for Portola Pharmaceuticals Inc (PTLA) : Benchmarked against the leading firms in its primary industry, Benchmarked against the average for publicly-held companies (U. Scot Blocker is 47 years old and was born on 3/12/1971. Sign Up. View the basic PTLA stock chart on Yahoo Finance. After losing more than half of its market cap last year, the biotech's share price Aug 18, 2016 Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa (andexanet alfa) Feb 17, 2016 Portola Pharmaceuticals Announces BLA for Andexanet Alfa Accepted for Review by FDA Dec 18, 2015 Portola Pharmaceuticals Completes BLA Where are Portola Pharmaceuticals' (NASDAQ:PTLA) earnings headed? View PTLA's earnings history and consensus earnings estimates from top-rated Wall Street analysts at MarketBeat. The average volume was noted at 1365. Latest Breaking news and Headlines on Portola Pharmaceuticals (PTLA) stock from Seeking Alpha. Have breaking news sent to your inbox. 07:42 PM ET. This is the historical insider ownership of Portola Pharmaceuticals Inc. Dr. Jan 06, 2019 · Portola Pharmaceuticals, Inc. B. It is located on the San Francisco Peninsula and has a significant shoreline on San Francisco Bay. 84 (10. At the time of this reporting, Wolff Henry Ward is the Director of Portola Pharmaceuticals Inc . Developing and commercializing therapies that advance patient care in thrombosis and other hematologic diseases. Responsibilities: Responsible for realization of medical/scientific objectives for the MSL team Access information on acutely ill medical patients who may be at risk of venous thromboemolism. Latest Breaking news and Headlines on Portola Pharmaceuticals (PTLA) stock from Seeking Alpha. For Portola Pharmaceuticals, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered 36 Portola Pharmaceuticals jobs, including salaries, reviews, and other job information posted anonymously by Portola Pharmaceuticals employees. Get hired. It now has employee strength of 150 and went public in 2013. in a news release and in a regulatory filing published on Monday, June 4, 2018, William (Bill) Lis leaves his post as Chief Executive Officer at the biopharmaceutical company after around eight years in the role, effective August 1, 2018. Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. Burlingame is a city in San Mateo County, California. In February 2009, Novartis bought worldwide rights to develop it further, intending to conduct Phase III studies and commercialise the drug. 29B, we can say that PTLA stock is a Small Cap stock Portola Pharmaceuticals, Inc. portola pharmaceuticals history Historical stock prices are provided with the open, high, low, close In USA industry, Portola Pharmaceuticals, Inc. Do you think you'll buy? Do you already have active trades now? Portola Pharmaceuticals (NASDAQ: PTLA) lagged the market last month by falling 11% compared to a 0. Its FDA-approved News for Portola Pharmaceuticals Inc. Dier, Executive Vice President, Chief Financial Officer and Chief Business Officer at Portola Pharmaceuticals, Inc. Supplied by Portola Pharmaceuticals, Inc. The substance was originally developed by Portola Pharmaceuticals, with Phase II clinical trials conducted around 2008–2011. 77. Description. This is because Bevyxxa is a blood thinner medicine that reduces blood clotting. Considering the last full year performance, the price performance is -66. Portola previously said FDA review of AndexXa would run through May 4 …Portola shares have fallen 60% in 2018, while the S&P 500 SPX, +3. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. History More than a century ago, with the guidance and support of his Highness Maharaja Sayajirao Gaekwad, a great mind with business acumen along with two geniuses of Chemistry, conceived Alembic Chemical Works Company Limited. Portola is located on the Middle Fork of the Feather River, and was named after Spanish exp Portola Pharmaceuticals, Inc. Find Portola Pharmaceuticals jobs on Glassdoor. Andexanet alfa is a recombinant modified form of factor Xa (FXa), designed to bind to and reverse the anticoagulant activity of FXa inhibitors. Portola Pharmaceuticals market cap history and chart from 2011 to 2018. 6%. Developing and commercializing therapies that advance patient care in thrombosis and other hematologic diseases. 18% from its 52 week-bottom price value. Historical Data for Portola Pharmaceuticals Inc. Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, …Cara Miller is VP:IR & Corporate Communications at Portola Pharmaceuticals Inc. Portola Pharmaceuticals (NASDAQ:PTLA) is enjoying the best year ever -- at least in terms of stock performance. 1. Portola Pharmaceuticals was formed in 2003 in South San Francisco, California. Real-time trade and investing ideas on Portola Pharmaceuticals Inc. This page will remain active for a few weeks following the event so attendees can access information. About Portola Pharmaceuticals, Inc. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, t he Portola Pharmaceuticals, Inc. (PTLA), including history of rankings (upgrades, downgrades). 2017 Annual Report . See Cara Miller's compensation, career history, education, & memberships. Sign up to StockTwits to save a watchlist for easy access to your favorite stocks. Read the news as it happens! Hypothetical Dividend Dividend History…Portola Pharmaceuticals, Inc. Bigham currently is a member of the board of directors of InMediata and has held several directorships, including Avila Therapeutics, Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Avedro, and Valeritas. 94, its 52 week- peak value and changed 15. Finbox. Portola Pharmaceuticals (PTLA) has 0 splits in our Portola Pharmaceuticals stock split history database. He was an original member of the team that spun off Portola Pharmaceuticals from Millennium Pharmaceuticals. 00, for a total value of $564,000. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of diluted shares outstanding. INDICATION. Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals shares have a SELL rating. 35 million outstanding shares currently held by using all its shareholders, including share blocks held by using institutional investors and limited shares owned via the organization’s officials and insiders. Portola Pharmaceuticals Inc Portola Pharmaceuticals Inc Categorized under Pharmaceutical Preparations. 68. Yes. PTLA 19. Looking at Portola Pharma market capitalization, which currently stands at $1. , a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. You will work to successfully identify navigate the hospital formulary process and meet the needs of a broad spectrum of customers. Get Portola Pharmaceuticals Inc (PTLA:NASDAQ) real-time stock quotes, news and financial information from CNBC. If you are looking for stocks with good return, Portola Pharmaceuticals, Inc can be a profitable investment option. 43% has fallen 0. provides specialty pharmaceutical products. The driving forces. Includes Opening, Closing, High, and Low trade prices for the day, as well as the day's volume and closing price change. Dier's network of 43 business contacts. (AROC) snatched the consideration from Investors, when its current damaging picture was seen that is promoting bad performance. It is not precise, just to let you know. State Street Corp lifted its holdings in shares of Portola Pharmaceuticals by 5. (AP) — Portola Pharmaceuticals Inc. PTLA from the largest community of traders and investors. DelMar Pharmaceuticals Inc. Food and Drug Administration in June 2017. Shoba has 8 jobs listed on their profile. below in FB comments. During the same quarter in the prior year, the company earned ($1. Where are Portola Pharmaceuticals' (NASDAQ:PTLA) earnings headed? View PTLA's earnings history and consensus earnings estimates from top-rated Wall Street analysts at MarketBeat. ’s book to market ratio is at 0. View daily, weekly or monthly format back to when Portola Pharmaceuticals, Inc. I will eventually write a longer article on this topic and about pharmaceuticals in general. 59% positive lead over its 52-week low and showed downward move of -70. historical price data and PTLA charts. The company was founded on September, 2, 2003 and named after Gaspar de Portolà, who was the first european to see San Francisco Portola Pharmaceuticals, Inc. Their average twelve-month price target is $35. Homcy joined Third Rock Ventures, a venture capital firm, where he is now a partner. Portola Pharmaceuticals was formed in 2003 in South San Francisco, California. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that Portola Pharmaceuticals, Inc. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. Change the date range, chart type and compare Portola Pharmaceuticals, Inc. is a biopharmaceutical company . Treatment for: Prevention of Venous Thromboembolism Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized for an acute medical illness. At Walletinvestor. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that Portola Pharmaceuticals is relatively new to biotech investors and was one of many biotechs to IPO last year. Portola Pharma shares slide 6% on news of delay in EU review of treatment for bleeding MarketWatch. Portola Pharmaceuticals stock research in summary. nginx/1. Portola Pharmaceuticals is a biotechnology company focused on developing and commercializing novel therapeutics. The company insiders' interest are more aligned with external shareholders in this case. : We are providing you with this proxy statement supplement to provide additional information resulting from events that occurred subsequent to About Portola Pharmaceuticals, Inc. Skilled in medical See stock analyst recommendations for Portola Pharmaceuticals, Inc. (PTLA) Ratings History Chart Access our full ratings history chart by signing up now! Portola Pharmaceuticals, Inc. Portola Pharmaceuticals' reported first-quarter financials after the closing bell on Monday, and while the company is still a long way from reporting a profit to investors, it did provide Portola Pharmaceuticals, Inc. Portola Pharmaceuticals' (NASDAQ:PTLA) won FDA approval of their first commercial drug, Bevyxxa in June, and that sent shares skyrocketing. 88%. * An * after P or S in the Buy/Sell column means the transaction was filed by the insider as open market, but it was marked as private transaction by insidercow's proprietary method “Portola is at an important inflection point in its history as the company turns its focus to the successful launches of Andexxa and Bevyxxa, and a potential third medicine progressing to late Summary Background. (NASDAQ:PTLA) has "Outperform" rating given on Friday, February 24 by Oppenheimer. (NASDAQ:PTLA) is Buy (Score: 2. Discover historical prices for PTLA stock on Yahoo Finance. Portola Pharmaceuticals, Inc. The official website of the Federal Trade Commission, protecting America’s consumers for over 100 years. NEW YORK -- Shares of Portola Pharmaceuticals were sliding 16. Current: Portola Pharmaceuticals; Experienced medical communications specialist with a demonstrated history of working in the pharmaceutical industry. Capital Since 2003, we've partnered with over 440 innovative companies in the technology, life sciences, sustainable + renewable, and special situations verticals. Operations Portola Pharmaceuticals is a biopharmaceutical company developing innovative drugs for the treatment of cardiovascular and inflammatory diseases PortolaÕs two most advanced programs are in Phase II clinical trials: 1) betrixaban, an oral, once-daily Factor Xa inhibitor being developed for stroke prevention in patients with atrial fibrillation (SPAF) and for prevention of venous Enter up to 25 symbols separated by commas or spaces in the text box below. (PTLA) share price, charts, trades & the UK's most popular discussion forums. See Mardi C Dier's compensation, career history, education, & memberships. On the other end of this stick, Portola's pipeline is magnitudes stronger than Omeros' pipeline. For Portola Pharmaceuticals, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered Portola Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc is a biopharmaceutical company. It is a little bit of Portola Pharmaceuticals, Inc. Biggar is a partner at Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. Bevyxxa is a Trademark by Portola Pharmaceuticals, Inc. " About AGC Biologics AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a strong commitment to deliver the highest standard of service to our clients and partners. on Wednesday reported a loss of $91. 11:14 AM ET. Marketplace Seeking Alpha SUBSCRIBE. Portola Pharmaceuticals' (NASDAQ: PTLA) investors would probably like a mulligan on 2016. Common Stock historical prices, historical stock prices, historical prices, historical data. Portola. Portola is at an important inflection point in its history as the Company turns its focus to the successful launches of Andexxa and Bevyxxa, and a potential third medicine progressing to late-stage development. The Company offers novel therapeutics for thrombosis, hematologic disorders, and inflammation. Currently, she lives in Portola Valley, CA. insider trades are listed in the following table, followed by a table containing the full transaction history. 63% to reach at the floor price of $22. Targeted Therapies in the Fight Against Cancer. Free forex prices, toplists, indices and lots more. The latest Tweets from Portola Pharma (@portola_pharma). During its last trading session, Stock traded with the total exchanged volume of 1. , a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. Overview. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. Bevyxxa can increase the risk of bleeding, which can be serious and may lead to death. The company’s products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein 2017 Annual Report . you have a history of difficult or repeated epidural or spinal punctures; you have a history of problems with your spine or have had surgery on your spine; If you take BEVYXXA and receive spinal anesthesia or have a spinal puncture, your healthcare provider should watch you closely for symptoms of spinal or epidural blood clots. , San Francisco with expertise in: Clinical Trials, Hematology and Oncology. We do not make recommendations as to particular securities or derivative instruments, and do not advocate the purchase or sale of any security or investment by you or any other individual. The company reported its earnings, blowing expectations out Portola Pharmaceuticals (Nasdaq: PTLA) is a biopharmaceutical company founded in 2003 and headquartered in South San Francisco, Californi Portola Pharmaceuticals (Nasdaq: PTLA) is a Portola Pharmaceuticals, Inc. The company grew by raising money through private and public funding to the extent of $450mn including a $100mn Initial Public Offering IPO in 2013. Basel, Switzerland, 5 September 2017 – Lonza, a global leader in chemical and biological manufacturing, today announced that it has entered into a long-term commercial supply agreement with Portola Pharmaceuticals, Inc. 2017 Technology Fast 500 Recognizing growth The fastest growing technology companies Updated November 9, 2017 at 7 p. PTLA has had a horrible history with filings with the FDA, we have all commented about it and have seen the results. (PTLA) Portola Pharmaceuticals holds sales signals from both short- and long-term moving averages. 28 (-1. (stock ticker symbol PTLA ). See the complete profile on LinkedIn and discover Shoba’s I am initiating coverage of Portola Pharmaceuticals with a Buy and a 2021 price target of $426. 05 million shares. contact Portola Pharmaceuticals You have a history of problems . The current consensus rating for Portola Pharmaceuticals, Inc. On June 23, Portola Pharmaceuticals (NASDAQ: PTLA) jumped 45% on the news that its first commercial drug, Bevyxxa, secured FDA approval. PTLA Dividend History & Description — Portola Pharmaceuticals, Inc. As of the most recent market close, this stock’s last recorded price was $16. The decline added to prior significant losses to leave the biotech stock well behind the broader market, with a drop of over 50% so far in 2018. com's Pulse Picks. Portola Pharmaceuticals (PTLA) has 0 splits in our Portola Pharmaceuticals stock split history database. Stock splits are used by Portola Pharmaceuticals, Inc. He received his BS from the University of Virginia and his MBA from Stanford University. PORTOLA PHARMACEUTICALS INC Share Price Today; PORTOLA PHARMACEUTICALS INC Share Price Chart; PORTOLA PHARMACEUTICALS INC News; PORTOLA PHARMACEUTICALS INC Share Price History; PORTOLA PHARMACEUTICALS INC Financials; PORTOLA PHARMACEUTICALS INC Trades; PORTOLA PHARMACEUTICALS INC Level 2; Add PORTOLA PHARMACEUTICALS INC to Watchlist John T. Todd Campbell owns shares of Portola Pharmaceuticals. Pharmaceuticals. Free real-time prices, trades, and chat. It became a public limited company in 1996 and was listed in NASDAQ. It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. The first manufacturing facility was set up in New Haven in 1992, the first-in-human clinical trials for eculizumab began in 1996-98 period. The Motley Fool owns shares of and Portola Pharmaceuticals, Inc. They are bad value, are riskily financed, and show below average growth. Pharmaceuticals Inc. Our records show it was established in 2003 and incorporated in California. Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that have the potential to represent significant advances in the fields of thrombosis and hematology. Common Stock historical prices, historical stock prices, historical prices, historical data Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. Shares in Portola began to shoot higher in early 2015 after the company announced in Jan. (PTLA) $ 18. Portola Pharmaceuticals discovers and develops innovative therapeutics based on targets with established proof of concept that are designed to provide significant advances over current treatments for cardiovascular and autoimmune/inflammatory diseases. Todd owns E. View the latest PTLA stock quote and chart on MSN Money. Request full access to PitchBook. 50 , a potential (5 Detailed institutional ownership and holders of Portola Pharmaceuticals, Inc. focused on developing life-saving therapeutics in thrombosis and hematology. Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concepts that are engineered to provide significant advances over current treatments for cardiovascular disease, inflammatory disease and cancer. PTLA historical prices, PTLA historical data,Portola Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of Portola Pharmaceuticals, Inc. The stock was sold at an average price of $47. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the …See stock analyst recommendations for Portola Pharmaceuticals, Inc. Yet the market opportunity for Bevyxxa could total in the Company: Portola Pharmaceuticals, Inc. View daily, weekly or monthly formats back to when Portola Pharmaceuticals, Inc. 3% during the second quarter. Portola Pharma stock price history comprises of 10 years of historical data, or the data since the inception of the company. 29k: 2:41 PM EST 17-Dec-2018 At the time of this reporting, Renton Hollings is the Director of Portola Pharmaceuticals Inc . The FDA has approved betrixaban (Bevyxxa, Portola Pharmaceuticals), the first anticoagulant for hospital and extended-duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. com we make a concerted effort to provide the most accurate Earnings Calendar available by cross checking various sources including newswire feeds, brokerages, exchanges and individual corporate investor relations websites. Kristine Harjes owns shares of Johnson and Johnson and Portola Pharmaceuticals. shares jumped Monday after the company announced that the Food and Drug Administration had given an approval that should lead to the launch of its Andexxa drug. (stock ticker symbol PTLA). The article Portola Pharmaceuticals' Betrixaban Misses Mark, But All Is Not Lost originally appeared on Fool. going further with portola pharmaceuticals inc Just doing our first step, which was to evaluate the covered call while avoiding earnings is clever -- certainly an analysis that gets us ahead of most casual option traders. You will be a member of Portola’s dynamic sales team focused on launching and selling novel compounds in the hospital setting. 23. 57 -0. We recommend selling Portola Pharmaceuticals shares. Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, …Dec 30, 2018 · Portola Pharmaceuticals, Inc. Portola (Nasdaq: PTLA) is a biopharma co. Shows up to the last year's worth of daily historical stock prices for PTLA stock. Read 219 publications, and contact John T. In an effort to better understand the company's pipeline and upcoming catalysts Wikimedia Commons has media related to Pharmaceutical companies of the United States Companies portal The main article for this category is Pharmaceutical company . 2017 in review. Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. 84K shares while its relative volume was seen at 0. 3 million in its third quarter. On this page you will find a helpful summary of Portola Pharmaceuticals. By aggregating the opinions and predictions of our best trading systems (trading bots), we come up with a general prediction. msn back to msn home money. against other companies. 75% over its 52-week high. This security is traded as a secondary listing on the Open Market. Bevyxxa can cause serious side effects: • The most common side effect of Bevyxxa is bleeding. 12. Stephen R. On Thursday, shares in Portola Pharmaceuticals, Inc. The population was 2,104 at the 2010 census, down from 2,227 at the 2000 census. As with Portola, our commitment to deliver marketed products is prioritized across our entire organization. 2 Portola Pharmaceuticals has $81 highest and $24 lowest target. History Related History. The FDA approved Portola Pharmaceuticals' (NASDAQ: PTLA) first commercial drug, Bevyxxa, in June, but changes to its manufacturing process resulted in the filing of a prior approval supplement The FDA approved Portola Pharmaceuticals' (NASDAQ: PTLA) first commercial drug, Bevyxxa, in June, but changes to its manufacturing process resulted in the filing of a prior approval supplement Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The stock ended the day 4. is headquartered in South San Francisco, California. to keep share prices within reasonable numbers to encourage investment. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that c Mr. 21. We have been doing this for a long time. 15) EPS. The stock analysis for Portola Pharmaceuticals, Inc. Community Stock Ratings for Portola Pharmaceuticals, Inc. stock quote and PTLA charts. It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. (PTLA) retreated -4. Actinium is a leading biotechnology company developing targeted radioimmunotherapies for the treatment of cancer patients with unmet needs. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases. io Fair Value SEE FAIR VALUE BREAKDOWN Talk about Portola Pharmaceuticals Inc. It is a change at short notice. Mardi Dier is Exec VP/CFO/Head:Commercial Activities at Portola Pharmaceuticals Inc. Although I will say that as far as bad management goes, Portola is much worse than Omeros' management used to be. 64% Portola Pharma stock price ended the last trading day at $19. SOUTH SAN FRANCISCO, Calif. Read our 2017 Annual Report, 10-K, and Shareholder Letter. As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals to Outperform from Neutral, with a $70 price target, saying the shares sold off following Q2 and that he now sees an attractive entry point. filed as a Statement & Designation By Foreign Corporation in the State of California on Tuesday, September 23, 2003 and is approximately fifteen years old, according to public records filed with California Secretary of State. Select up to six indices , securities or other market indicators . (PTLA) - See ratings for PTLA from other NASDAQ Community members and submit your own rating for PTLA. com we predict future values with technical analysis for wide selection of stocks like Portola Pharmaceuticals, Inc (PTLA). 39%. m. Sign up. FDA approval history for Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) used to treat Reversal of Anticoagulant Activity of Factor Xa Inhibitors. 84 on heavy trading volume early Thursday afternoon after the company received a complete response letter from the FDA for Biogen Idec executes deals with Portola Pharmaceuticals for an oral therapy for autoimmune diseases, and with Samsung Biologics on biosimilars to form a joint venture now called Samsung Bioepis. As we look at Portola Pharmaceuticals Inc we note that a covered call is one of the most common implementations of an option strategy, but the analysis completed when employing the covered call often times lacks the necessary rigor especially surrounding earnings. Become a member for free. Biggar, M. Home / Top News / Factors of Influence in 2018, Key Indicators and Opportunity within Portola Pharmaceuticals, Cable One, Marriot Vacations Worldwide, United Technologies, Park-Ohio, and BioScrip As part of the execution of Portola Pharmaceuticals’ strategy, he/she, as a member of Medical Affairs, will work closely with the Clinical Development, Commercial and Marketing functions. Todd Campbell owns shares of Celgene, Medivation, and Portola Pharmaceuticals. Dive deeper with interactive charts and top stories of Portola Pharmaceuticals Inc. Curnutte of Portola Pharmaceuticals Inc. , South San Francisco, CA, on Equilar BoardEdge to see current and past work history and gain access to Mardi C. To explore Portola Pharmaceuticals’s full profile, request a free trial. Special Black Friday Offer | Save 50% Now. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. 07% and finalized at the price of $20. Insiders are officers, directors, or significant investors in a company. is a part of Healthcare sector and belongs to Biotechnology industry. Optionistics is not a registered investment advisor or broker-dealer. To the Stockholders of Portola Pharmaceuticals, Inc. stock was issued. Portola Pharmaceuticals is a part of Healthcare sector and belongs to Biotechnology industry. The South San Francisco-based company said it had a loss of $1. It is usually better to buy companies with large insider ownership. SOUTH SAN FRANCISCO — Portola Pharmaceuticals Inc. D. you have a history of problems with your spine or have had surgery on your spine If you take BEVYXXA and receive spinal anesthesia or have a spinal puncture, your healthcare provider should watch you closely for symptoms of spinal or epidural blood clots. with share price and PTLA stock charts. com is tracked by us since September, 2016. (PTLA) stock price ended its day with gain 5. It is not precise. See this page for all insider trading activities at Portola Pharmaceuticals Inc . History. Previous to BioTMC, he was a Sr. News on Portola Pharmaceuticals continually updated from thousands of sources around the net. The Company’s first medicine Bevyxxa ® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U. About Portola. (PTLA), including valuation measures, fiscal year financial statistics, trading records, share statistics and more. If you sign up for our portal - for free - , then your selections maintain . Company: Portola Pharmaceuticals, Inc. . 11 Dec 2018 Portola Pharmaceuticals expects a formal opinion from CHMP for the MAA of andexanet alfa in February 2019 ; 11 Dec 2018 The Committee for Medicinal Products for Human Use extends the review of MAA of andexanet alfa for Haemorrhage 11 Dec 2018 Portola Pharmaceuticals expects a formal opinion from CHMP for the MAA of andexanet alfa in February 2019 ; 11 Dec 2018 The Committee for Medicinal Products for Human Use extends the review of MAA of andexanet alfa for Haemorrhage Portola Pharmaceuticals. 45. IMPORTANT INFORMATION ABOUT BEVYXXA. 26 as the company is set to share its latest quarterly earnings after to closing bell on May 05, 2016. (PTLA) is based on the analysis and stock picks of our best trading systems. See stock analyst recommendations for Portola Pharmaceuticals, Inc. Stock quote for Portola Pharmaceuticals, Inc. Curnutte on ResearchGate View Shoba Gopalan’s profile on LinkedIn, the world's largest professional community. to join Portola at such a pivotal moment in the Company's history. Dividend History for Portola Pharmaceuticals (PTLA). 75) with a consensus target price of $61. (PTLA) on Wednesday reported a loss of $71. 49%) Volume: 528. was founded in 2003 by David Phillips. 8 million in its fourth quarter. 73 million. The city is named after diplomat Anson Burlingame and is often referred to as the City of Trees due to its numerous eucalyptus groves. S. (PTLA) have 67. Portola Pharmaceuticals Inc (NASDAQ: PTLA) is having an incredibly strong start to the trading session this morning, and for good reason. These symbols will be available during your session for use on applicable pages. Treatment for: Prevention of Venous Thromboembolism Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult …Portola Pharmaceuticals, Inc. DelMar Pharmaceuticals, Inc. 118478 while the book to market mean difference is -0. , Portola Pharmaceuticals, PTLA Archrock, Inc. (NASDAQ: PTLA) is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Free real-time prices, and the most active stock market forums. Bevyxxa is indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. Jan 10, 2017 So a quick recap of events Recent History. Find the latest Dividend (TTM) for Portola Pharmaceuticals, Inc. The company focuses on areas of throm The incredible story behind the greatest lost treasure in US history Judge Postpones Flynn Sentencing After Harshly Rebuking Him Dec 11 (Reuters) - Portola Pharmaceuticals Inc: Earnings History: Past Earnings Statistics and Earnings Trendline At OptionSlam. Common Stock Common Stock (PTLA) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Sometimes Joi goes by various nicknames including joi l ferrando and joi l m deaser. April 05, 2018. Director at Global Blood Therapeutics becoming the first employee of this Third Rock Ventures founded company. HealthCare Royalty Partners is an investment firm that purchases royalties and uses debt-like structures to invest in commercial stage assets. Please do not create a new PRS account if your organization already has one. Whether you're a curious investor or a successful start-up seeking venture financing, explore our impressive venture lending portfolio here. 4% of their value last Portola Pharmaceuticals upgraded to Outperform at Credit Suisse. has been the Chairman of our Board of Directors since June 2016 and has been a director since 2013. December 11, 2018 December 11, 2018 Braden Nelson 0 Comments Archrock, AROC, Inc. 05738. 00. To help you get a sense of the short to long-term trend of Portola Pharmaceuticals, there is a stock chart which you can easily adjust to the time frame of your choosing -- anywhere from three months to 10 years. recorded a trading volume of 654,679 shares, which was below the three months average volume of 907,806 shares. headquarters are located in South San Francisco, California. Jun 4, 2018 Portola is at an important inflection point in its history as the Company turns its focus to the successful launches of Andexxa and Bevyxxa, and a Developing and commercializing therapies that advance patient care in thrombosis and other hematologic diseases. Common Stock (PTLA) last sale data in real-time at NASDAQ. Get all the key statistics for Portola Pharmaceuticals, Inc. 4% increase in the S&P 500, according to data provided by S&P Global Market Intelligence. Get your Free Trial here. This indicator tells you how a company is currently valued in terms of Book to Market compared to its average Book to Market over the past 10 years. , a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. (PTLA) Ratings History Table Portola Pharmaceuticals, Inc. November 20, 2018. Portola Pharmaceuticals stock price, live market quote, shares value, historical data, intraday chart, earnings per share, dividend yield, market capitalization and news updated on Thursday, December 6, 2018. View the executive profile of Mardi C. is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of The organizations on this list already have Protocol Registration and Results System (PRS) accounts. It now has employee strength of 150 and went Developing and commercializing therapies that advance patient care in thrombosis and other hematologic diseases. PTLA Real Time Stock Quote - Get Portola Pharmaceuticals, Inc. Filed in May 6 (2014), the PORTOLA PHARMACEUTICALS covers House mark for a full line of pharmaceutical products; pharmaceutical preparations for use in oncology and hematology; pharmaceutical preparations for the treatment of coagulation disorders, thrombosis, hematologic cancers, and inflammation Pharmaceutical preparations for use in oncology and hematology; pharmaceutical preparations for the treatment of coagulation disorders, thrombosis, hematologic cancers, and inflammation Portola Pharmaceuticals, Inc. The issuer’s publication requirements are in accordance with the regulations of the respective home market and may considerably fall behind those of the Regulated Market. Thank you to all who attended the Spring Meeting. VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. 25% to $19. , Ph. (PTLA) finalized the Monday at price of $38. 6 Wall Street analysts have issued ratings and price targets for Portola Pharmaceuticals in the last 12 months. (PTLA), including new, increased, descreased, and sold out positions. (Portola) for coagulation factor Xa (recombinant), inactivated- zhzo with the proprietary name ANDEXXA, and International Nonproprietary Name (INN) andexanet alfa . Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, t he William Lis, Chief Executive Officer, Portola Pharmaceuticals, Inc. This is an extensive initial report on Portola Pharmaceuticals that is organized into five parts: Investment Overview for Portola is a summary of the key investment issues. The recent session has given its stock price a 9. Food and Drug Administration (FDA). Latest stock price today and the US's most active stock market forums. 38. PTLA historical prices, PTLA historical data,Portola Pharmaceuticals, Inc. Dividend (TTM) is a widely used stock evaluation measure. com. Portola Pharmaceuticals price history, PTLA 1 day chart with daily, weekly, monthly prices and market capitalizations In 2010, Dr. The Allstate Corporation(NYSE: ALL)’s stock value took a rollercoaster ride since the start of the recent year, with the year-to-date change of -13. , the address on file for this trademark is 270 East Grand Avenue, South San Francisco, CA 94080 Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the Get the Pulse of the Market with StreetInsider. Short Ratio of stock is 6. After the company experienced two painful setbacks to key programs, shares lost 56. is a biopharmaceutical company. Portola Pharmaceuticals has two highly anticipated clinical-stage programs under review by the U. Portola Pharmaceuticals Where are Portola Pharmaceuticals' (NASDAQ:PTLA) earnings headed? View PTLA's earnings history and consensus earnings estimates from top-rated Wall Street analysts at MarketBeat. Sometimes Scot goes by various nicknames including scot d blocker and scot david Joi Deaser is 48 years old and was born on 7/7/1970. Alexion Pharmaceuticals was founded by Leonard Bell in 1992 at Science Park in New Haven, Connecticut. portola pharmaceuticals historyThe company was founded on September, 2, 2003 and named after Gaspar de Portolà, who was the first european to see San Francisco portola pharmaceuticals history. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that About Portola Pharmaceuticals, Inc. You’re viewing a free company profile from the PitchBook Platform. com. Sign up Portola Pharmaceuticals, Inc. Portola Pharmaceuticals' financing deals have significantly strengthened its balance sheet, but the company's long-term survival depends significantly on the timing of FDA decisions on betrixaban About Portola Pharmaceuticals, Inc. PTLA Dividend History & Description — Portola Pharmaceuticals, Inc. is a publicly-traded company that operates in the Biotherapeutics industry. The South San Francisco, California-based company said “Bristol-Myers Squibb and Pfizer’s agreement with Portola is an important step forward toward the goal of delivering the first reversal agent for Factor Xa inhibitors, including Eliquis, to patients in Japan. Read the news as it happens! Hypothetical Dividend Dividend History. Portola Pharmaceuticals Inc. portola. , a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. StockTalk Analysis News Blogs. A legacy of innovation, a portfolio of promise ™ We are a specialty pharmaceutical company with more than 25 years of experience focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. (AROC) Snapshot: In latest trading activity; Archrock, Inc. 50, suggesting that the stock has a possible upside of 117. The business enterprise has shares float of 65. History (including family history) or symptoms of, or risk factors for bleeding History (including family history) of or risk factors for a hypercoagulable or thrombotic condition Absolute/relative contraindication to anticoagulation or treatment with specific anticoagulants Historical prices for Portola Pharmaceuticals, Inc. Over the time it has been ranked as high as 647 699 in the world, while most of its traffic comes from USA, where it reached as high as 141 469 position. Currently, he lives in Portola Valley, CA; and previously lived in San Francisco, CA and San Francisco, CA. Oppenheimer upgraded Portola Pharmaceuticals (NASDAQ: PTLA) from Perform to Outperform with a price Split History. You can adjust market indicators on the home page according to your needs . Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases. Note that in the past Wolff Henry Ward also reported insider trading activities as an insider of the following companies: This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in patients with relapsed/refractory chronic lymphocytic leukemia or non-hodgkin lymphoma This is an open-label, Phase 1/2a, multi dose, multi-center trial of orally administered Discover historical prices for PTLA stock on Yahoo Finance. Portola is the only incorporated city in Plumas County, California, United States. (NASDAQ: PTLA)’s stock value took a rollercoaster ride since the start of the recent year, with the year-to-date change of -32. Alnylam has secured its first approval, but history suggests that launch will be far from easy. ) in its industry, This includes financial results, ratios, vital statistics and metrics in one package with historical and current metrics and averages Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. 41 per 301 Moved Permanently. These are 2 Hold Ratings, 6 Buy Ratings . He served as president and chief executive officer of Portola Pharmaceuticals, Inc. Healthcare and biotech investors take note: Bevyxxa has a massive potential patient pool, and its drug class is already raking in billions of dollars a year. 23 after traded 517535 shares